Related Experiment Video
Updated: Jun 25, 2026

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
Targeting: the ADEPT story so far
1Medical Oncology, Imperial College London, UK. kbagshawe@googlemail.com
Abstract:
Antibody-directed enzyme prodrug therapy aims to restrict the action of a cytotoxic drug to cancer sites. An enzyme that has no human analogue is delivered to cancer sites by attachment to an antibody directed at a tumour associated antigen. In a second step an antibody or other agent inactivates and clears enzyme from blood. The third step is administration of a low toxicity prodrug that is a substrate for the enzyme thus generating a potent cytotoxic agent at cancer sites. Encouraging results were obtained with this system in small scale clinical trials using unrefined agents. During the past 10 years attempts have been made to reduce the system to two components. Although these have met with some success it is now accepted that future progress requires all three components.
Insights
Antibody-directed enzyme prodrug therapy uses a three-component system to target cytotoxic drugs specifically to cancer cells. This approach enhances drug efficacy and minimizes systemic toxicity for cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-directed enzyme prodrug therapy (ADEPT) is a targeted cancer treatment strategy.
- It aims to localize potent cytotoxic drugs exclusively at tumor sites, minimizing systemic exposure.
Purpose of the Study:
- To review the principles and progress of ADEPT.
- To highlight the importance of a three-component system for optimal therapeutic outcomes.
Main Methods:
- Delivery of a non-human enzyme conjugated to a tumor-targeting antibody to cancer sites.
- Administration of a prodrug that is selectively activated by the enzyme into a cytotoxic agent at the tumor.
- Use of a secondary agent to clear circulating enzyme from the bloodstream.
Main Results:
- Small-scale clinical trials using unrefined agents showed encouraging results.
- Recent efforts to simplify the system to two components have had limited success.
Conclusions:
- The three-component ADEPT system is crucial for future advancements in targeted cancer therapy.
- Maintaining all three components is essential for maximizing efficacy and safety.
More Related Videos
Related Concept Videos
Affinity and Avidity
Robbers Cave
Hindsight Biases
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Confirmation Biases
The Stanford Prison Experiment

